ReviewHeliyon2025
Design of studies on neoadjuvant therapy for intrahepatic cholangiocarcinoma.
Review in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biocompatibility and Multifunctional Biological Evaluation of Flower-Shaped Ag₂CO₃ and Ag/Ag₂CO₃ Nanostructures in Diabetic Albino Mice.Applied biochemistry and biotechnology · 2026Article
- Living for the 'gram: analysing the online footprint of lupus using a qualitative social media listening tool.Clinical rheumatology · 2026Article
- Surgical management of intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a narrative review of principles, technical nuances, and emerging strategies.Journal of liver cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high recurrence rate and dismal prognosis of localized intrahepatic cholangiocarcinoma (ICC) indicate the unmet need for effective adjuvant and neoadjuvant therapy. In recent years, progress has been made in immunotherapy and targeted therapy for the treatment of advanced biliary tract cancer (BTC), leading to clinical exploration of the provision of these therapies in the perioperative period. Based on years of experience in clinical research on hepatobiliary cancers, the authors discuss the design of studies on neoadjuvant therapy for ICC, aiming to provide references for future neoadjuvant studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.